Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) insider Bros. Advisors Lp Baker bought 885,000 shares of the company’s stock in a transaction on Thursday, October 5th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $15,045,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) traded down 15.83% during mid-day trading on Friday, hitting $25.25. 2,164,741 shares of the company’s stock were exchanged. Rhythm Pharmaceuticals Inc has a 52 week low of $23.82 and a 52 week high of $30.55.

TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/06/bros-advisors-lp-baker-purchases-885000-shares-of-rhythm-pharmaceuticals-inc-rytm-stock.html.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Receive News & Ratings for Rhythm Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.